SEP 13, 2012 12:00 PM PDT

Consumer Response to Direct-to-Consumer Personal Genomic Testing

SPONSORED BY: Thermo Fisher Scientific, Thermo Fisher Scientific
23 31 1411

  • Director of Social Sciences & Bioethics, Assistant Professor, Scripps Translational Science Institute, Scripps Health & The Scripps Research Institute
      Dr. Bloss is an Assistant Professor, as well as Director of Social Sciences and Bioethics at the Scripps Translational Science Institute. Her research is funded by the National Institutes of Health and is focused on investigating individuals' behavioral and psychological responses to disclosure of personal genomic information. She is the lead researcher on STSI's Scripps Genomic Health Initiative, and her work on this project was recently published in the New England Journal of Medicine and has been highlighted at a number of national and international scientific meetings. She has also presented invited testimony on consumer genomics before the Food and Drug Administration Advisory Panel.
      Dr. Bloss' other research interests include developing ways of combining genomics with traditional disease risk factors to make predictions about disease development, progression and response to treatment, as well as designing effective health interventions that leverage genomic information. She also conducts genetic association studies and has several collaborations to investigate the genetic underpinnings of neurological, behavioral, and other health-related phenotypes.
      Dr. Bloss received her B.A. in Psychology from Smith College, her Ph.D. in Clinical Psychology from the University of California, San Diego, and completed a predoctoral internship in clinical neuropsychology at the University of Florida. Dr. Bloss completed a post-doctoral fellowship in statistical genetics and genomic medicine at The Scripps Research Institute.



    Direct-to-Consumer (DTC) genome-wide disease risk profiling is currently available to individuals and provides information about one's genetic risk for a range of common polygenic diseases. The Scripps Genomic Health Initiative (SGHI) was launched in 2008 with the aim of evaluating the psychological, behavioral, and clinical impacts of DTC genomic testing on consumers. In a recently published study of over 2,000 individuals who underwent genomic profiling with the Navigenics Health Compass, we found minimal psychological, behavioral, or clinical impacts of testing at short-term follow-up. In this presentation, we will discuss new data based on long-term follow-up of the same group of consumers, as well as analyses evaluating the impact of disease risk testing for relevant subgroups of individuals, including those with or without a family history of disease. Preliminary data on the impact of DTC pharmacogenomic testing, as well as genetic ancestry testing will also be presented. Finally, new directions for research in this area will be discussed.


    Show Resources
    Loading Comments...